Medical grade sensor for continuous hydration monitoring and early detection of fluid imbalances.

Informazioni relative al progetto

ReBalans

ID dell’accordo di sovvenzione: 969065

DOI

10.3030/969065

Progetto chiuso

Data della firma CE 17 Febbraio 2021

Data di avvio 1 Marzo 2021

Data di completamento 29 Febbraio 2024

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 3 567 500,00

Contributo UE

€ 2 497 250,00

Coordinato da

MODE SENSORS AS
Norway

Periodic Reporting for period 2 - ReBalans (Medical grade sensor for continuous hydration monitoring and early detection of fluid imbalances.)

Periodo di rendicontazione: 2022-03-01 al 2024-02-29

Sintesi del contesto e degli obiettivi generali del progetto

Fluid disorders represent a major problem in healthcare. Especially for patients in risk of dehydration or overhydration, such as heart and renal disease patients in hospital wards or elderly population with reduced thirst and cognitive problems. Improper fluid management has important implications for patients, caregivers and economies: increase mortality, increase risk of suffering co-morbidities (infections, longer hospital stays, acute kidney injuries) and increase costs (e.g. proper hydration could lead to €1bn savings in UK per year). Current practice for fluid monitoring uses Fluid Balance Charts, which are inaccurate, incomplete, time-consuming and cumbersome to complete. Mode Sensors developed a revolutionary solution for fluid monitoring, the Re:Balans patch sensor, a non-invasive, connected, disposable and wearable sensor for remote and continuous monitoring of body hydration. Re:Balans is built 1) with robust sensor combination to meet medical level accuracy data, and 2) to be user-friendly and fit into everyday worker and patient procedures. Re:Balans will be a game-changer in the healthcare because: 1) it has better accuracy than the best-practice method in clinical settings; 2) it is cheaper and more efficient to use than current alternatives. Re:Balans will have a major impact by: 1) reducing unnecessary costs and casualties by preventing dehydration, such as comorbidities, readmission to hospital or longer hospital stays; 2) improving doctors and nurses daily activities, substituting time-consuming measurements by automatic, remote and continuous accurate data, and 3) strengthen healthcare systems with a solution that directly addresses the EU’s challenges of ageing population, multimorbidity and healthcare worker shortages.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Since the End of Reporting Period 1 (28th of February 2022) until project completion (29th of February 2024), MODE has achieved the following key results:
• Updated patent and IPR strategy.
• Updated risk matrix and mitigation actions.
• Developed and verified new sensor-patch with improved performance in terms of wearability, water, resistance, stability, and bioimpedance measurement accuracy.
• Developed and verified production testers responsible for automatic programming, verification of performance, etc. suited high-volume manufacturing.
• Improved the on-device hydration calculation algorithm by implementing quality assurance, the proprietary tissue model, other compensation filters using data from the other sensors on the sensor-patch, hereunder accelerometer and thermistor.
• Developed prototype for IoT-gateway and API Bluetooth interface, incl. integrator manual.
• Finalized clinical validation report from study on nursing home residents.
• Performed all safety and performance testing required for regulatory submission and clearance, incl. biological safety testing, electrical safety, bench-performance testing, etc.
• Completed technical files for 510(K) Clearance and CE-marking, incl. verification & validation documentation, labelling, instructions for use, etc.
• Implemented a full QMS according ISO13485 and performed internal audits and notified body pre-assessments proving compliance with the standard.
• Updated business plan, competitive analysis, and financial forecast.
• Secured three commercial co-development agreements with multinational commercial partners in med-tech, military, welfare technology markets.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Re:Balans® is the 1st spectral bioimpedance wearable device able to filter out confounding factors and give a correct and complete representation of the user’s daily fluid levels. This gives many opportunities to progress beyond the state of the art, which MODE intends to patent, exploit commercially, and make a socio-economic impact by creating value for patients, caregivers, and the healthcare system:
• Improving millions of lives by preventing disease, health complications, etc. in vulnerable individuals.
• Reducing cost in healthcare by preventing hospital admissions and readmission due to fluid imbalance.
• Making the healthcare sector more sustainable by providing a tool for remote care.

Re:Balans® prototype for clinical trials and demonstration

Improved Re:Balans® sensor-patch for regulatory clearance

Re:Balans® demo-system illustration